Compare CDNA & SCL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CDNA | SCL |
|---|---|---|
| Founded | 1998 | 1932 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Package Goods/Cosmetics |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.1B |
| IPO Year | 2007 | 1994 |
| Metric | CDNA | SCL |
|---|---|---|
| Price | $17.06 | $46.62 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 1 |
| Target Price | $27.33 | ★ $75.00 |
| AVG Volume (30 Days) | ★ 539.5K | 144.7K |
| Earning Date | 05-13-2026 | 05-27-2026 |
| Dividend Yield | N/A | ★ 3.37% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 2.05 |
| Revenue | $48,324,000.00 | ★ $1,803,737,000.00 |
| Revenue This Year | $15.37 | $6.98 |
| Revenue Next Year | $11.23 | $4.69 |
| P/E Ratio | ★ N/A | $22.91 |
| Revenue Growth | ★ 18.93 | N/A |
| 52 Week Low | $10.96 | $41.82 |
| 52 Week High | $21.49 | $68.00 |
| Indicator | CDNA | SCL |
|---|---|---|
| Relative Strength Index (RSI) | 37.34 | 27.75 |
| Support Level | $16.74 | $41.98 |
| Resistance Level | $17.09 | $50.37 |
| Average True Range (ATR) | 0.83 | 1.79 |
| MACD | -0.21 | -0.83 |
| Stochastic Oscillator | 23.77 | 7.75 |
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically the company generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.
Stepan Co manufactures and sells a variety of chemicals and chemical-based products. The company organizes itself into three segments based on product type. The surfactants segment, which generates the majority of revenue, sells cleaning agents used in detergents, shampoos, body wash, fabric softeners, toothpastes, and other personal-care products. The polymers segment sells polyurethane used to manufacture rigid foam for thermal insulation, as well as phthalic anhydride used to make plastic components for the construction, automotive, and boating industries. The specialty products segment sells chemicals used in food and flavoring. The majority of Stepan's revenue comes from the United States, followed by France, Poland, the United Kingdom, Brazil, Mexico, and other countries.